Innovator U.S. Equity Buffer ETF - May (BATS: BMAY)

Dernières nouvelles pour Innovator U.S. Equity Buffer ETF - May (BATS:BMAY)

The Fund invests at least 80 percent of its net assets in FLexible EXchange Options that reference the SPDR S&P 500 ETF Trust. FLEX Options are exchange-traded options contracts with uniquely customizable terms. Although guaranteed for settlement by the Options Clearing Corporation. FLEX Options are still subject to counterparty risk with the OCC and may be less liquid than more traditional exchange-traded options

Innovator US Equity Buffer ETF - May

Innovator U.S. Equity Buffer ETF - May

All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway
Vistagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTGN#NASDAQ">VTGN</a>), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD).
The repeat dose study is a small exploratory U.S. Phase 2 multi-center, randomized, double-blind, placebo-controlled, three-arm clinical trial designed to assess the efficacy, safety, and tolerability of a repeat dose of fasedienol (3.2 micrograms) in adults with SAD during a public speaking challenge conducted in a clinical setting. The three dosing arms will be fasedienol followed by fasedienol (total 6.4 micrograms), fasedienol followed by placebo (total 3.2 micrograms), and placebo followed by placebo, with the second dose in each arm administered ten minutes after the initial dose. Other than the repeat dose and the additional study arm, the study is similar in design to the ongoing PALISADE Phase 3 studies for the acute treatment of adults with SAD, including an open-label extension.

Biotech

News

General

VTGN

Vistagen Announces Phase 3 Program For Social Anxiety Disorder With Fasedienol; First Enrollment In U.S. Study For Efficacy, Safety, Tolerability During Public Speaking Challenge

Offerings

CLDI

Calidi Biotherapeutics Prices 5M Share Offering At $0.85/Share

Guidance

LiveOne Says In Dec, Subsidiary Enters Agreement Expected To Generate $25M In 2025

Coca‑Cola Consolidated, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) announced today that Executive Vice President and Chief Financial Officer (CFO), Scott Anthony, will retire effective March 31, 2025. Mr. Anthony has served as the Company's CFO since 2018.
The Company also announced that Matthew J. Blickley will assume the role of Executive Vice President and Chief Financial Officer, effective April&nbsp;1, 2025. Mr. Blickey joined Coca‑Cola Consolidated in 2014 and currently serves as Senior Vice President, Financial Planning and Chief Accounting Officer. He will continue to serve as the Company's Chief Accounting Officer following this change. During his tenure with the Company, Mr. Blickley has served in a variety of financial roles of increasing responsibility, including Corporate Controller. He is a certified public accountant and began his career with PricewaterhouseCoopers LLP. Mr. Blickley will serve on the Company's executive leadership team and will report to Dave Katz, President and Chief Operating Officer.

Management

COKE

Coca-Cola Consolidated CFO Scott Anthony To Retire, Effective March 31, 2025; Company Names Matt Blickley As New CFO

Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are just "too low to sell," according to Jim Cramer, host of CNBC&#8217;s "<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>." 
Hold the stock and let "the dividend do the job," Cramer advises, preferring to wait for "some good news" <a href="https://www.benzinga.com/general/biotech/23/03/31319372/seagens-43b-deal-to-double-pfizers-early-stage-oncology-pipeline-seagen-says-is-right-step">on the Seagen acquisition</a>.
Pfizer stock is down more than 7% over the past year. With the Covid wave having past, the pharma giant is in talks to extend its collaboration with medical AI start-up firm PostEra to design antibody-drug conjugates.
Turning to Vertex Pharmaceuticals Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) new wonder drug suzetrigine, which received FDA approval last year, Cramer said it was disappointing that the drug does not seem to be working. "I was praying they would have something that wouldn&#8217;t be addictive," he added.
Although the pharma company has several "great drugs," there seems to be a limited upside to the stock because suzetrigine was supposed to be the "drug of the future for Vertex," Cramer added.
When asked about Serve Robotics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>), Cramer suggested Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) for exposure to the sector. Calling Nvidia the "king of robots," he further said, "There's nobody else."
Cramer said he would be a seller of QuantumScape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>). Referring to the steep decline in Powell Industries Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) shares, Cramer said, "I did not see that coming." The decline has been a "big, big disappointment," he added.
Price Action
<ul>
<li>Pfizer's stock declined by 1% to close at $26.86 on Wednesday.</li>
<li>Shares of Vertex Pharmaceuticals Inc settled higher by 0.93% at $412.11.</li>
<li>Serve Robotics tanked almost 10% on Wednesday.</li>
<li>Nvidia's share price ended the trading session almost flat.</li>
<li>QuantumScape's stock plunged 9% to close at $5.72.</li>
<li>Shares of Powell Industries fell 3.26% to $229.38.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnin</a>gs</li>
</ul>
Image: Shutterstock

Markets

Media

Trading Ideas

NVDA

POWL

SERV

VRTX

Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure

The earnings results for E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) for Q3 were made public on Friday, January 10, 2025 at 07:45 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
E2open Parent Holdings missed estimated earnings by 0.0%, reporting an EPS of $0.05 versus an estimate of $0.05.
Revenue was down $4.75 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
In the previous quarter, the company missed on EPS by $0.0, resulting in a 22.0% drop change in the share price the following day.
Here's a look at E2open Parent Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.05</td>
<td>0.04</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.05</td>
<td>0.04</td>
<td>0.05</td>
<td>0.04</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>154.81M</td>
<td>155.03M</td>
<td>155.39M</td>
<td>154.46M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>152.19M</td>
<td>151.20M</td>
<td>158.45M</td>
<td>156.40M</td>
</tr>
</tbody>
</table>

To track all earnings releases for E2open Parent Holdings <a href="https://www.benzinga.com/quote/ETWO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ETWO

E2open Parent Holdings: Q3 Earnings Insights

GRYP

Gryphon Digital Mining Signs Agreement To Acquire Captus Energy's Industrial Site, Believes will Enable Expansion Into AI And HPC Data Center Infrastructure

American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) ("American Rebel" or the "Company"), a designer, manufacturer, and marketer of branded safes, personal security, self-defense products, apparel, and American Rebel Beer (<a href="https://www.globenewswire.com/Tracker?data=07r4E0q1pTO_wzjuC3HdfqPFDv6Aig7gHm0kO-cnsl_MAWFdPucChII7NWoo9YjFnetdNcApk18qWXSESFqGIy6MMB77Nv8_3ltrnwETV5sEdD1dj7vM7Y3mZTA7J3B3">www.americanrebelbeer.com</a>), is proud to announce the delivery of the initial shipment of American Rebel Light Beer to its recently established distribution partner, Clark Distributing Company (<a href="https://www.globenewswire.com/Tracker?data=oxU1v7khEMWjNwIPnDWb_8_uQX03cSQQBufMInOwr8hsVmfAZlqzOvUnAoXQwevLy-63cSGQ5CnRgQ9YUdGTbA==">www.ccclark.com</a>), for the Commonwealth of Kentucky announced on October 30, 2024. The opening order is American Rebel Beer's largest order to date, 400% larger than typical opening orders, as American Rebel Light Beer continues to rapidly grow and expand its national footprint.
Kentucky is a key strategic state as American Rebel Light Lager Beer continues to rapidly grow its distribution partnerships throughout the Southeastern United States. Clark Distributing Company, a premier distributor serving more than 5,000 retail and restaurant customers throughout Kentucky, has placed the largest opening order of American Rebel Light Beer, marking the official launch of the product's availability in the state. Kentucky residents can now enjoy American Rebel Premium Light Lager Beer that not only is great tasting but unapologetically celebrates true fundamental American values. Clark Distributing Company covers 97 counties out of 120 total, representing 81% of Kentucky's counties and serving 67% of the state's population.

AREB

American Rebel Announce The Delivery Of The Initial Shipment Of American Rebel Light Beer To Its Recently Established Distribution Partner, Clark Distributing Company

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $102 price target.

Price Target

Reiteration

Analyst Ratings

VKTX

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue
Management to Host Virtual Investor Webinar Today at 11:00 a.m. Eastern Time
EDEN PRAIRIE, Minn., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced preliminary unaudited revenue for the fiscal first quarter ended December 31, 2024.
In the first quarter of fiscal 2025, the Company expects total revenue to increase to a record $6.2 million, compared to $1.0 million the first quarter of fiscal 2024. The first quarter of fiscal 2025 includes a one-time $3.0 million payment of collaboration revenue from the <a href="https://www.globenewswire.com/Tracker?data=VRrUyAQNXcnh4BTxpSfmU6n8nw_9zQ8MYBFeONmFk4hJq1FV6ZnnPS9-m13cwK0FzrLRU3aVfPs7JAs4DXh6IpRjrRJrqDsrvut5OnKtEc95J-VNdpJMI17MyecuUt1rZkmG_fnWvjdgbt4SFGiQY9Wz53ya-KCzquUtLA0jE69N80hL4v7Vvfi7IsBJM8oP3Ibp7AOMdEZewCBJsTJExWKoaR7K-bWGiiJx5Oljg-b0DzuljXFh8J18MyTzSV5yR59iRThDbIEbpGanfY6--dkLR1gjilBjzj_b_ZSbN3fBHel2f12dZjW0XKzgbCsDgLMCbOYwFiFTbugDwW0dnl39zCSYBHlGqTxjiNcVekE-CtC7qb0P8IjythymPEFZ">expanded distribution agreement with Zimmer Biomet</a> for commercialization of the Company's OneRF&#x2122; Ablation System, which was announced in October 2024 and is expected to be fully recognized in the first quarter of fiscal 2025. As previously announced, the agreement with Zimmer will provide NeuroOne with an additional milestone payment if certain performance criteria are achieved and is expected to generate meaningful revenue and expand product margins for the Company.
In addition to the collaboration revenue of $3.0 million, the Company expects product revenues to increase 227% to $3.2 million in the first quarter of fiscal 2025, compared to product revenue of $1.0 million in the first quarter of fiscal 2024. For the full year of fiscal 2025, the Company is reiterating guidance specific to product revenues, which exclude collaboration revenues, to range between $8.0 and $10.0 million, with product gross margin to range between 47% and 51%.

NMTC

NeuroOne Expects $6.2M Q1 Fiscal 2025 Revenue, Including $3M One-Time Payment From Zimmer Biomet; Product Revenue Jumps 227% To $3.2M; FY25 Product Revenue Guidance Of $8M-$10M With 47%-51% Gross Margin

Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price of $3.50 per share. All of the shares are being offered by Amylyx. In addition, Amylyx has granted the underwriter a 30-day option to purchase up to an additional 2,571,428 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Amylyx from this offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercise of the underwriter's option to purchase additional shares.
Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, to advance preparations for commercialization and pipeline programs, for working capital and for general corporate purposes.
The offering is expected to close on or about January 13, 2025, subject to the satisfaction of customary closing conditions.
Leerink Partners is acting as sole bookrunning manager for the offering.

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Prices $60M Public Offering Of 17.1M Shares At A Price Of $3.50 Each

Macro Economic Events

Econ #s

Economics

CORRECTION: US Private Nonfarm Payrolls (Dec) 223K vs 135K Est.; Prior 182K

HC Wainwright &amp; Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and raises the price target from $14 to $15.

ANGO

HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $15

<ul>
<li>LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody&#xAE;</li>
<li>First-in-human study enrolling adult patients with CD123-expressing AML or MDS</li>
<li>Initial Phase 1 data read-out expected by year-end 2025 &nbsp;</li>
</ul>
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=M1A3tf0LgeIlv5L5m0ZZ1RsgDY82AHsA7xK6oc-XKGtvkZAAdO77VY1y1RZQZSpGJFAIGfOQDq6z7E9YXUyUMzW9TSGfJ3pNIhEpT-z4NsY=">LAVA Therapeutics N.V. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>, "LAVA, " "the Company"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody&#xAE; platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody&#xAE;, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

LVTX

LAVA Therapeutics Announces First Patient Dosed In Phase 1 Study Of Bispecific Anti-CD123 Gammabody LAVA-1266 For AML And MDS; Initial Data Expected By Year-End 2025

Macro Notification

US Nonfarm Payrolls (Dec) 256K vs 164K Est.

Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) shares are trading higher premarket after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42908301/delta-air-lines-announces-december-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">fourth-quarter 2024 results</a>.
Delta reported fourth-quarter adj. operating revenue growth of 5.7% year-over-year to $14.437 billion. GAAP operating revenue was $15.56 billion (+9.4% YoY), beating the consensus of $14.212 billion.
Adjusted average fuel price was $2.34 per gallon, down from $3.00 from last year&#8217;s quarter. Adjusted EPS was $1.85 (+44.5% YoY), <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus of $1.76.</a>
Related: <a target="_blank" href="https://www.benzinga.com/general/travel/25/01/42899701/delta-q4-earnings-preview-can-bullish-trends-keep-the-stock-flying-high" rel="noreferrer noopener">Delta Q4 Earnings Preview: Can Bullish Trends Keep The Stock Flying High?</a>
Total passenger revenue for the quarter grew 5% year over year to $12.815 billion; cargo revenue grew 32% year over year to $249 million, and Other revenue was $2.495 billion (+34% year over year).
Delta recorded an adjusted operating income of $1.735 billion, up from $1.33 billion YoY, with an adjusted operating margin of 12%, up ~230 bps.
Adjusted operating expenses increased by 3% YoY to $12.702 billion, and Adjusted Non-fuel costs were $9.9 billion for the quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42901060/delta-expands-premium-travel-experience-with-uber-youtube-and-joby-partnerships-unveiled-at-ces-2025" rel="noreferrer noopener">Delta Expands Premium Travel Experience with Uber, YouTube, and Joby Partnerships</a>
Delta generated an adjusted operating cash flow of $1.8 billion in the December quarter. Full-year adjusted operating cash flow reached $8.0 billion, with gross capital expenditures of $4.8 billion, resulting in $3.4 billion free cash flow for 2024.
Adjusted net debt at the December quarter-end decreased to $18 billion, a reduction of $3.6 billion from the end of 2023. Liquidity stood at $6.1 billion at year-end, including $3.1 billion in undrawn revolver capacity.
The passenger load factor was flat at 84%. DAL&#8217;s Air Traffic Liability ended the quarter at $7.1 billion.
&#8220;As we move into 2025, we expect strong demand for travel to continue, with consumers increasingly seeking the premium products and experiences that Delta provides. Our differentiated strategy and best-in-class operations, combined with demand strength and an increasingly constructive industry backdrop, position us to deliver the best financial year in Delta&#8217;s 100-year history, with pre-tax income greater than $6 billion, earnings per share greater than $7.35 and free cash flow of more than $4 billion,&#8221; commented Ed Bastian, Delta&#8217;s chief executive officer.
&#8220;As efficiency gains continue, we expect non-fuel unit cost growth to continue in the low-single digits for the full year 2025 as efficiencies offset the impact of slower capacity growth and continued investments in our people and the customer experience,&#8221; stated Dan Janki, Delta&#8217;s chief financial officer.
First Quarter 2025 Outlook (Non-GAAP): DAL&#8217;s total revenue is expected to grow 7% &#8211; 9% year-over-year with an operating margin of 6% &#8211; 8%. Earnings per share are forecasted between $0.70 and $1.00 versus the $0.77 estimate.
2025 Outlook: The company&#8217;s EPS is projected at greater than $7.35, reflecting 10%+ YoY growth and 19%+ on a non-GAAP basis.
Price Action: DAL shares are trading higher by 7.78% at $66.20 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42908495/us-stocks-to-open-on-a-tentative-note-as-traders-remain-cautious-ahead-of-fridays-crucial-jobs-data" target="_blank" rel="noreferrer noopener">US Stocks To Open On A Tentative Note As Traders Remain Cautious Ahead Of Friday&#8217;s Crucial Jobs Data</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Movers

Delta Takes Flight As Q4 Earnings Beat Expectations, Fueled By Premium Travel Demand And Efficiency Gains

ACM Research's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NYSE">ACMR</a>) short percent of float has risen 9.83% since its last report. The company recently reported that it has 4.31 million shares sold short, which is 9.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ACM Research Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736515823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ACM Research has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ACM Research's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ACM Research's peer group average for short interest as a percentage of float is 4.72%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ACMR

Peering Into ACM Research's Recent Short Interest

Intuitive Machines's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NYSE">LUNR</a>) short percent of float has fallen 4.79% since its last report. The company recently reported that it has 14.22 million shares sold short, which is 17.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Intuitive Machines Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736515818_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Intuitive Machines has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Intuitive Machines's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intuitive Machines's peer group average for short interest as a percentage of float is 6.18%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LUNR

Looking Into Intuitive Machines's Recent Short Interest

Stride's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) short percent of float has risen 10.31% since its last report. The company recently reported that it has 5.99 million shares sold short, which is 19.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Stride Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736515813_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Stride has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Stride's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Stride's peer group average for short interest as a percentage of float is 2.77%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Stride's Recent Short Interest

Mike Wilson, Morgan Stanley's chief investment officer, has some advice for anyone looking to advance in their career: Take risks. Be bold. And don't fear being wrong.
"You've got to be willing to take a stand on stuff," Wilson told Business Insider. "Whether it's in a meeting, with people you report to or pointing out things you don't agree with, kind of making a firm stance."
But here's the kicker: Wilson believes real success comes from doing what most people won't – betting against the crowd.
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></li>
</ul>
<h2 class="wp-block-heading">Why Contrarian Views Pay Off</h2>
Wilson says taking "personal risk" is where you can find real rewards, especially on Wall Street. The real money is made with "contrarian views," he explained. But it's not always easy and involves "accepting the idea that you're going to be wrong along the way," he said. "Ultimately, how you deal with those consequences will determine whether you're successful or not."
In short: Play it safe and you'll miss the big wins.
<h2 class="wp-block-heading">Betting On Yourself</h2>
Wilson isn't just throwing out motivational sound bites. He's talking about taking risks that others shy away from. For him, being wrong occasionally is just part of the process.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
The key is to stick to your convictions, even if it feels uncomfortable. "On Wall Street, personal risk often means taking contrarian views," he added.
That advice doesn't just apply to Wall Street, though. It's a mindset anyone can use to advance their career or investments.
<h2 class="wp-block-heading">Learn From The Best</h2>
Wilson isn't the only one offering top-tier advice. Wall Street heavyweights like David Kostin of Goldman Sachs, BlackRock's Rick Rieder and Bloomberg's Anna Wong have also contributed.
Kostin's advice? Show up. "I can't imagine how a young person is going to actually absorb all the dimensionality of what's happening … and not be in the office," he said.
Rieder, meanwhile, suggests focusing on the future. "The world's changing faster than anybody really recognizes," he explained.
And Wong encourages curiosity: "Constantly being curious, even if there might not be an obvious payoff to it."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">The Takeaway</h2>
Wilson's advice is to Take a chance, go against the grain, be prepared to fail and not let that stop you.
For those willing to embrace risk, the personal and financial rewards could be worth it. As Wilson put it, personal risk often means being a contrarian.
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Comments

Innovator U.S. Equity Buffer ETF - May

Actualités

Dernières nouvelles pour Innovator U.S. Equity Buffer ETF - May (BATS:BMAY)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL